Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 September 2004, Vol. 104, No. 5, pp. 1442-1449.
Prepublished online as a Blood First Edition Paper on May 20, 2004; DOI 10.1182/blood-2004-02-0588.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-02-0588v1
104/5/1442    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harata, M.
Right arrow Articles by Asano, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harata, M.
Right arrow Articles by Asano, S.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Immunotherapy
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome–positive acute lymphoblastic leukemia cells

Masamitsu Harata, Yasushi Soda, Kenzaburo Tani, Jun Ooi, Tomoko Takizawa, Minghan Chen, Yuansong Bai, Kiyoko Izawa, Seiichiro Kobayashi, Akira Tomonari, Fumitaka Nagamura, Satoshi Takahashi, Kaoru Uchimaru, Tohru Iseki, Takashi Tsuji, Tsuneo A. Takahashi, Kanji Sugita, Shinpei Nakazawa, Arinobu Tojo, Kazuo Maruyama, and Shigetaka Asano

From the Division of Molecular Therapy, Advanced Clinical Research Center, University of Tokyo, Tokyo, Japan; the Department of Hematology/Oncology, Research Hospital, University of Tokyo, Tokyo, Japan; the Division of Cell Processing, Institute of Medical Science, University of Tokyo, Tokyo, Japan; the Division of Clinical Research and Development, Therapeutic Product Development, Amgen Limited, Tokyo, Japan; the Department of Advanced Molecular and Cell Therapy, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan; the Faculty of Pharmaceutical Science, Teikyo University, Kanagawa, Japan; the Department of Industrial Science and Technology, Science University of Tokyo, Chiba, Japan; and the Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis despite intensive therapeutic intervention. Recently, imatinib, a BCR-ABL tyrosine kinase inhibitor, has been proven to be an effective treatment for Ph+ ALL, but nearly all patients rapidly acquire resistance. High-dose imatinib administration might overcome this resistance; however, systemic toxicities would likely limit this approach. Therefore, a new delivery system allowing for the specific targeting of imatinib is urgently needed. Because almost all Ph+ ALL cells express CD19 on their surface, we have developed an immunoliposome carrying anti-CD19 antibody (CD19-liposomes). The internalization efficiency of the CD19-liposomes approached 100% in all Ph+ ALL cells but was very low in CD19– cells. The cytocidal effect of imatinib-encapsulated CD19-liposomes (imatinib-CD19-liposomes) on Ph+ ALL cell lines and primary leukemia cells from patients with Ph+ ALL was much greater than that of imatinib with or without control liposomes. Importantly, the imatinib-CD19-liposomes did not affect the colony formation of CD34+ hematopoietic cells, even at inhibitory concentration of free imatinib. Taken together, these data clearly demonstrate that the imatinib-CD19-liposomes induced specific and efficient death of Ph+ ALL cells. This new therapeutic approach might be a useful treatment for Ph+ ALL with fewer side effects than free imatinib.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Targeting ALL leukemia
Jerald P. Radich
Blood 2004 104: 1235-1236. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
A. Kotani, D. Ha, J. Hsieh, P. K. Rao, D. Schotte, M. L. den Boer, S. A. Armstrong, and H. F. Lodish
miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221
Blood, November 5, 2009; 114(19): 4169 - 4178.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020